^
    5d
    ARC-27: A Study of AB801 Monotherapy and Combination Therapy in Participants With Advanced Malignancies (clinicaltrials.gov)
    P1, N=91, Active, not recruiting, Arcus Biosciences, Inc. | Recruiting --> Active, not recruiting
    Enrollment closed
    |
    EGFR (Epidermal growth factor receptor) • ALK (Anaplastic lymphoma kinase) • MET (MET proto-oncogene, receptor tyrosine kinase) • ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS) • NTRK (Neurotrophic receptor tyrosine kinase)
    |
    EGFR mutation • ALK mutation • MET mutation
    |
    docetaxel
    7d
    A Multikinase Inhibitor AX-0085 Blocks FGFR1 Activation to Overcomes Osimertinib Resistance in Non-Small Cell Lung Cancer. (PubMed, Biomedicines)
    Additionally, AX-0085 inhibited AXL and FGFR1-dependent oncogenic events, including cell proliferation, clonogenicity, and migration. The dual inhibition of AXL and FGFR1 by AX-0085 can overcome acquired osimertinib resistance, supporting its potential as a therapeutic strategy for treating patients with osimertinib-resistant tumors.
    Journal
    |
    EGFR (Epidermal growth factor receptor) • FGFR1 (Fibroblast growth factor receptor 1)
    |
    EGFR mutation
    |
    Tagrisso (osimertinib) • AX-0085 • simmitinib (SYHA1817)
    14d
    Cerebraca-02/3: Comparison of Cerebraca Wafer Plus Temozolomide Versus Temozolomide Alone in Recurrent Glioblastoma (clinicaltrials.gov)
    P2/3, N=175, Not yet recruiting, Everfront Biotech Co., Ltd.
    New P2/3 trial
    |
    temozolomide
    16d
    Structural Analysis of Tilvestamab in Complex with AXL. (PubMed, ACS Omega)
    Both SAXS and cryo-EM confirmed successful complex formation between the three proteins, and a low-resolution 3D model for the tilvestamab-AXL complex is presented. The data allow for sample optimization for high-resolution structural biology, as well as designing mutations that could alter binding affinity and specificity.
    Journal
    |
    AXL (AXL Receptor Tyrosine Kinase) • GAS6 (Growth arrest specific 6)
    |
    tilvestamab (BGB149)
    1m
    A Study to Evaluate Adrixetinib (Q702) in Adults With Active Chronic Graft-Versus-Host Disease (clinicaltrials.gov)
    P1, N=18, Recruiting, Qurient Co., Ltd. | Not yet recruiting --> Recruiting
    Enrollment open
    |
    adrixetinib (Q702)
    1m
    Oral Axl/Mer/CSF1R Selective Tyrosine Kinase Inhibitor in Patients With Advanced Solid Tumor (clinicaltrials.gov)
    P1, N=51, Completed, Qurient Co., Ltd. | Active, not recruiting --> Completed | N=78 --> 51 | Trial completion date: Feb 2025 --> Dec 2025 | Trial primary completion date: Dec 2024 --> Dec 2025
    Trial completion • Enrollment change • Trial completion date • Trial primary completion date
    |
    adrixetinib (Q702)
    2ms
    KEYNOTE-C62: Testing Experimental Anti-cancer Drug SLC-391 With an Approved Immunotherapy Drug, Pembrolizumab, for Advanced Lung Cancers (clinicaltrials.gov)
    P1/2, N=36, Terminated, SignalChem Lifesciences Corporation | N=92 --> 36 | Trial completion date: Sep 2028 --> Dec 2025 | Recruiting --> Terminated | Trial primary completion date: Sep 2026 --> Dec 2025; Lack of efficacy and enrollment challenges
    Enrollment change • Trial completion date • Trial termination • Trial primary completion date
    |
    PD-L1 (Programmed death ligand 1) • KRAS (KRAS proto-oncogene GTPase) • ALK (Anaplastic lymphoma kinase) • ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS)
    |
    PD-L1 expression • PD-L1 overexpression
    |
    Keytruda (pembrolizumab) • SLC-391
    2ms
    Anexelekto (Axl)/Mer inhibitor tamnorzatinib in patients with relapsed/refractory acute myeloid leukaemia: Results from a phase I (monotherapy) and phase II (combination with venetoclax) clinical study. (PubMed, Acta Haematol)
    Tamnorzatinib alone and in combination with venetoclax was safe and well tolerated but failed to induce robust clinical efficacy in R/R AML.
    P1 data • P2 data • Journal
    |
    AXL (AXL Receptor Tyrosine Kinase) • MERTK (MER Proto-Oncogene, Tyrosine Kinase)
    |
    Venclexta (venetoclax) • tamnorzatinib (ONO-7475)
    2ms
    CD146+ pericyte-like lung cancer brain metastatic stem cells promote tumor angiogenesis through dual regulatory effects on the VEGF/VEGFR axis. (PubMed, Theranostics)
    However, bevacizumab (Bev) shows limited therapeutic effects on NSCLC BrM...Targeting CD146 by imaprelimab or AXL by bemcentinib exhibits more effective anti-angiogenic effects than Bev for BrM in vivo. These findings provide novel anti-vascular strategies for BrM. CD146+ BrM-CSCs promotes high vascularization of lung cancer brain metastases through dual enhancement of VEGF/VEFGR, which suggests that targeting CD146 is a novel anti-vascular strategy for BrM.
    Journal
    |
    AXL (AXL Receptor Tyrosine Kinase) • KDR (Kinase insert domain receptor) • GAS6 (Growth arrest specific 6) • MCAM (Melanoma Cell Adhesion Molecule)
    |
    Avastin (bevacizumab) • bemcentinib (BGB324)
    2ms
    Revealing the mechanism of Tilvestamab in treating cancer from a single-molecule perspective using atomic force microscopy. (PubMed, Anal Chim Acta)
    Our study reveals that tilvestamab's anti-cancer efficacy arises from superior kinetic stability in AXL binding and direct modulation of cellular biomechanics. By enhancing membrane rigidity, tilvestamab impairs cancer cell migration and proliferation-key drivers of metastasis. These findings provide the biomechanical rationale for tilvestamab's therapeutic activity, positioning it as a promising agent for targeting AXL-dependent cancers through mechanopharmacological mechanisms.
    Journal
    |
    GAS6 (Growth arrest specific 6)
    |
    tilvestamab (BGB149)
    2ms
    AXL inhibition improves the therapeutic efficacy of trastuzumab in high-risk endometrial cancer. (PubMed, Gynecol Oncol)
    Our findings support the combination of batiraxcept and trastuzumab as a promising therapeutic strategy for aggressive HER2+ endometrial cancer.
    Journal
    |
    LDHA (Lactate dehydrogenase A) • AURKA (Aurora kinase A)
    |
    HER-2 expression
    |
    Herceptin (trastuzumab) • batiraxcept (AVB-500)
    3ms
    COAXIN: Avelumab in Combination With AVB-S6-500 in Patients With Advanced Urothelial Carcinoma (clinicaltrials.gov)
    P1, N=19, Active, not recruiting, University of Oklahoma | Trial completion date: Sep 2025 --> Feb 2026
    Trial completion date
    |
    Bavencio (avelumab) • batiraxcept (AVB-500)